Inhibition of human natural killer (NK) activity and antibody dependent cellular cytotoxicity (ADCC) by lipomodulin, a phospholipase inhibitory protein.
A highly purified preparation of lipomodulin, a phospholipase-inhibitory protein from rabbit neutrophils treated with glucocorticoids, inhibited NK and antibody-dependent cellular cytotoxicity (ADCC) activities of human peripheral blood lymphocytes in a dose-dependent manner. The presence of lipomodulin during the early period of the cytotoxicity assay was necessary to obtain maximal inhibition. The inhibition of NK or ADCC activity by lipomodulin was greater when effector cells were treated with lipomodulin than when target cells were incubated with lipomodulin. As lipomodulin did not block binding of effector cells to target cells, our results suggest that lipomodulin inhibits the cytolytic phase of NK and ADCC activities after binding to target cells, and imply that phospholipase(s) may be involved in NK and ADCC activities.
D017302:Annexins; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects*; D002135:Calcium-Binding Proteins; D006023:Glycoproteins; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D010740:Phospholipases / Q000037:antagonists & inhibitors*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D011506:Proteins / Q000494:pharmacology*; D011961:Receptors, Fc / Q000378:metabolism; D017452:Receptors, IgG; D012397:Rosette Formation; D013997:Time Factors
D017302:Annexins; D002135:Calcium-Binding Proteins; D006023:Glycoproteins; D011506:Proteins; D011961:Receptors, Fc; D017452:Receptors, IgG; C030958:lipomodulin; D010740:Phospholipases; D010741:Phospholipases A